KCM
EW icon

Kingdon Capital Management’s Edwards Lifesciences EW Stock Holding History

Kingdon Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-251,400
Closed -$19.6M – 75
2025
Q3 		$19.6M Buy
251,400
+160,100
+175% +$12.5M 2.43% 7
2025
Q2 		$7.14M Buy
+91,300
New +$6.81M 0.96% 44
2022
Q4 		– Sell
-141,000
Closed -$11.7M – 63
2022
Q3 		$11.7M Buy
+141,000
New +$13.6M 1.49% 19
2015
Q3 		– Sell
-992,598
Closed -$23.6M – 140
2015
Q2 		$23.6M Buy
992,598
+829,398
+508% +$18.7M 0.92% 33
2015
Q1 		$3.88M Buy
+163,200
New +$3.66M 0.16% 123

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Kingdon Capital Management's EW Position: Q4 2025 in Review

Kingdon Capital Management sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 251,400 shares — an estimated $19.6M sold.

Kingdon Capital Management first reported a position in EW in Q1 2015 and held it in 5 quarters. The position peaked at $23.6M in Q2 2015. 1,314 funds tracked by Wall St. Rank hold EW as of Q4 2025.

  • Kingdon Capital Management reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
  • Kingdon Capital Management sold 251,400 Edwards Lifesciences shares in Q4 2025, an estimated $19.6M.
  • Kingdon Capital Management first reported a position in Edwards Lifesciences in Q1 2015 and held it in 5 quarters.
  • Kingdon Capital Management's Edwards Lifesciences position peaked at $23.6M in Q2 2015.
  • 1,314 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on Kingdon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.